Evaluation of the distribution and excretion of [14C]-inclisiran following single subcutaneous administration in cynomolgus monkeys
Source : https://www.sciencedirect.com/science/article/abs/pii/S0041008X22001235?via=ihub
Inclisiran (small interfering RNA) acts in liver to lower plasma LDL cholesterol. * Pharmacokinetics and tissue distribution of 14 C-inclisiran were assessed in monkeys. * Radioactivity was highest in the...
Conclusion: This study confirmed the selective uptake of inclisiran by the liver, indicating that the N-acetylgalactosamine linker allows for selective uptake via the asialoglycoprotein receptors expressed on hepatocytes compared with other tissues that lack asialoglycoprotein receptors. The long tissue retention in the liver supports the...
Regulatory guidelines and preclinical tools to study the biodistribution of RNA therapeutics
Source : https://www.sciencedirect.com/science/article/pii/S0169409X22001260?via=ihub
The success of the messenger RNA-based COVID-19 vaccines of Moderna and Pfizer/BioNTech marks the beginning of a new chapter in modern medicine. However, the rapid rise of mRNA therapeutics has...
Conclusion: We conclude that this new and rapidly evolving class of medicines demands a multi-layered approach to fully understand its biodistribution and in vivo characteristics.
Liraglutide Attenuates Hepatic Ischemia-Reperfusion Injury by Modulating Macrophage Polarization
Source : https://www.frontiersin.org/articles/10.3389/fimmu.2022.869050/full
Ischemia-reperfusion injury (IRI) is a common complication associated with liver surgery, and macrophages play an important role in hepatic IRI. Liraglutide, a glucagon-like peptide-1 (GLP-1) analog primarily used to treat...
Conclusion: Collectively, our study indicates that liraglutide can ameliorate hepatic IRI by inhibiting macrophage polarization towards an inflammatory phenotype via GLP-1R. Its protective effect against liver IRI suggests that liraglutide may serve as a potential drug for the clinical treatment of liver IRI.
Drug Treatment of Hypercholesterolemia in Older Adults: Focus on Newer Agents - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35278206/
1 Department of Clinical Pharmacology and Pharmacoepidemiology, Medizinische Klinik, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. [email protected]. 2 Center for Geriatric Medicine, Heidelberg University, AGAPLESION Bethanien Hospital,...
Conclusion/Relevance: Especially in older patients needing high-intensity therapy despite polypharmacy or certain comedications, the absence of clinically relevant drug-drug interactions with the PCSK9 inhibitors and inclisiran might be an advantage.
